Celgene's (NASDAQ:CELG) new psoriatic arthritis drug Otezla isn't going to beat the current offerings from AbbVie (NYSE:ABBV), Johnson & Johnson (NYSE:JNJ), and Amgen (NASDAQ:AMGN) on an efficacy basis.

But it doesn't have too. Unlike Humira, Remicade, Enbrel, and the rest of the injected or infused biologics, Otezla is taken orally, giving Celgene a distinct advantage over AbbVie, Johnson & Johnson, and Amgen.

That doesn't mean Otezla will be an instant blockbuster though. As Fool contributor Brian Orelli and health-care bureau chief Max Macaluso discuss in the video below, Celgene needs to find a sweat spot, positioning Otezla between oral generics and the biologics doctors are comfortable prescribing.